Collaborations and License Agreements (Details)		1 Months Ended															3 Months Ended				12 Months Ended
	Aug. 01, 2019 USD ($)	Feb. 28, 2022 USD ($)	Aug. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)	Feb. 28, 2019 USD ($)	Nov. 30, 2018 USD ($)	Feb. 28, 2018 USD ($)	Oct. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Aug. 31, 2017 USD ($) milestone	Dec. 31, 2016	Aug. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2012 USD ($)	Mar. 31, 2010 USD ($)	Dec. 31, 2006 USD ($)	Mar. 31, 2022 USD ($) indication	Mar. 31, 2021 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2021 USD ($)	Apr. 30, 2014 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Trade receivables, net																	$ 12,943,000					$ 9,811,000
Revenues																	20,920,000	$ 1,920,000
EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development reimbursement received								$ 2,000,000	$ 4,000,000												$ 2,500,000
Number of milestones | milestone										3
Collaborations and license agreements, expected milestone receivable					$ 2,000,000	$ 2,000,000	$ 2,000,000			$ 2,000,000
Percentage of EUSA cost-sharing for TIVO-3 trial																					50.00%
Milestone payments to be received																	2,000,000
Potential milestone payment to be received																	2,000,000
Payments received in connection per indication																	$ 2,000,000
Eligible number of indications | indication																	3
Payments received in connection with additional indications																	$ 5,000,000
Potential payments received in connection with additional indications																	335,000,000
Research and development reimbursement milestone																	$ 20,000,000.0
Sublicense fee to earned milestone payments and royalties																	30.00%
Collaborations and license agreements, potential future payment as percentage of certain amounts the Company receives under sublicense agreements																	30.00%
Milestone payment																	$ 8,700,000
Milestone payment subject to sublicense fees																	20,000,000
Allocation of upfront payment					$ 600,000	$ 600,000	$ 600,000
Revenues																	800,000	900,000
KKC Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment																	0
Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues				$ 25,000,000															$ 2,800,000
Non refundable upfront payment																				$ 25,000,000
Milestone payment received			$ 2,800,000
Transaction price																			$ 27,800,000
Development and Regulatory Milestone Events | St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment		$ 2,300,000
Term after first sale												10 years
Termination notice period												6 months
Maximum | Biogen Idec International GmbH
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payments													$ 50,000,000
Maximum | Development and Regulatory Milestone Events | St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognition milestone method milestone payables																	12,100,000
Collaboration and Licensing Revenue | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate transaction price																	12,500,000				$ 12,500,000
Revenues																	600,000	500,000
Partnership licensing and royalty revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues																	834,000	854,000
Partnership licensing and royalty revenue | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues																	200,000	400,000
License | Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues																	0	0
Opt In To Planned Phase Three Study | Minimum | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eusa potential opt-In payment TIVO three trial																	8,700,000
Opt In To Planned Phase Three Study | Maximum | EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development reimbursement potential opt-in payment																	20,000,000.0
Astra Zeneca Agreement | Astra Zeneca Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Trade receivables, net																	500,000
FOCAL study | Biodesix
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty on future product sales, percentage of future licensing revenue																							25.00%
Required payment amount for agreement																							$ 2,500,000
FOCAL study | Minimum | Biodesix
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contribution percentage of clinical, regulatory, manufacturing and other costs																							50.00%
Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, one time milestone payment waived	$ 18,000,000.0
Collaborations and license agreements, expected milestone receivable																	390,700,000
Term of royalty payment obligations			10 years
Non refundable upfront payment	25,000,000
Milestone payment received			$ 2,800,000
Aggregate milestone payments																	$ 387,900,000
Licensing Agreements | St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received												$ 1,500,000
Licensing Agreements | KKC Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment receivable				$ 25,000,000
Collaborations and license agreements, one time milestone payment waived	$ 18,000,000
Upfront payment received																$ 5,000,000
Collaborations and license agreements, milestone payment															$ 10,000,000
Licensing Agreements | Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, potential future payment as percentage of certain amounts the Company receives under sublicense agreements																	30.00%
Term of royalty payment obligations											12 years
Royalties on the net sales																	$ 2,400,000	100,000
Licensing Agreements | FDA Marketing Approval | Kyowa Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment														$ 12,000,000
Research and development | Astra Zeneca Agreement | Astra Zeneca Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions																	$ 200,000	$ 200,000